SGO Annual Meeting on Women's Cancer

Rezetapopt showed a 44.4% response rate and durable responses over 8 months in ovarian cancer with p53 Y220C mutation, with mostly mild side effects.

Meetings like SGO drive collaboration and patient-centered progress, as Dr. Ginger J. Gardner highlights their role in advancing access and research.

Rezatapopt shows activity in TP53-mutated ovarian cancer, with responses seen across heavily pretreated patient groups and manageable side effects.

Dr. Kemi Doll reports that peer support helped Black women with high-risk endometrial cancer complete treatment in the SISTER trial.

Gynecologic oncology is evolving beyond surgery, with greater focus on systemic therapies, team-based care and improved patient outcomes.

Real-world data show ADCs benefit more diverse, older and pretreated patients, helping guide care and build confidence beyond limited clinical trial populations.

Treatment with Verzenio and letrozole may help control advanced or recurrent endometrial cancer for some patients, according to new research.

A phase 3 trial determined that Tivdak showed “game-changing results” for certain patients with cervical cancer, an expert told CURE®.

Cryocompression was found to be tolerable and effective in preventing chemotherapy-induced peripheral neuropathy in a small study.

Patients with ovarian cancer who utilized palliative care tended to have fewer hospital readmissions than those who did not, according to a recent study.

There were no major differences in survival when comparing intravenous and intraperitoneal chemotherapy plus Avastin in patients with advanced ovarian cancer, research shows.

“These results position mirvetuximab soravtansine to become a practice-changing, biomarker-driven, standard-of-care treatment option for patients with (high folate receptor-alpha)-positive, platinum-resistant ovarian cancer,” noted one of the study authors.

Zejula plus Avastin led to promising progression-free survival rates with no new side effects for patients with newly diagnosed, advanced ovarian cancer.

Jaron Mark, M.D., a gynecologic oncology fellow at Roswell Park Comprehensive Cancer Center, discusses the opioid crisis, and the steps that his institution is taking to combat potential addiction in women who undergo surgery for gynecologic cancer.

PARP inhibitors are generating a lot of excitement in the field of ovarian cancer. But how, exactly, do they work? CURE spoke with one expert to find out.

Knowing which kind of therapy works best can help in determining the ideal cancer care for patients.

“There has been a rapid expansion in the use of checkpoint inhibition in many solid tumor types,” lead author Emily Hinchcliff, M.D.

At the inaugural Ovarian Cancer Heroes gala, held in New Orleans ahead of the 49th Society of Gynecologic Oncology Annual Meeting on Women’s Cancers, four individuals — a physician, nurse navigator and two patient-turned-advocates — were awarded for the contributions they have made to increase awareness and advance research and education for ovarian cancer.

Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.

Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen.

Jubilee Brown, M.D., obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.

PARP inhibitors like niraparib are bringing big change to the treatment of ovarian cancer, says Kathleen N. Moore, M.D.

Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.

The PARP inhibitor niraparib proved to be effective in improving progression-free survival in recurrent ovarian cancer, according to a recent study.

Concern about vaccine safety and perceived lack of necessity remain the main reasons parents give for not having their teenage daughter vaccinated against HPV.

Jubilee Brown, M.D., answers some common questions about genetic counseling in patients with ovarian cancer.